View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. Comment
April 15, 2021

LoA Update: Outlook Therapeutics’ Phase III drug sees a 7 and 10-point LoA jump in two eye disease indications after positive safety data

The likelihood of approval (LoA) of Outlook Therapeutics’ (NASDAQ:OTLK) Phase III Lytenava (bevacizumab-vikg) in diabetic macular edema (DME) rose 7 points, with its prospects in branch retinal vein occlusion (BRVO) jumping by 10 as of 6 April, according to GlobalData’s LoA data.

By Sean Rai-Roche

The likelihood of approval (LoA) of Outlook Therapeutics’ (NASDAQ:OTLK) Phase III Lytenava (bevacizumab-vikg) in diabetic macular edema (DME) rose 7 points, with its prospects in branch retinal vein occlusion (BRVO) jumping by 10 as of 6 April, according to GlobalData’s LoA data. The increase was triggered after Outlook’s NORSE 3 trial in wet-AMD reported no unexpected safety events.

Free Report
img

What is the Global Healthcare and Pharma Market Q2 Outlook?

Given the background of high inflation, re-emerging supply chain issues, and the widespread macro-economic implications of the Ukraine conflict, the global pharmaceutical industry is facing an entirely new set of challenges following the turbulence of the COVID-19 pandemic. GlobalData’s World Markets Healthcare (WMH) service has released its latest Q2 forecast. This report incorporates the latest thinking on the opportunities and risks this new environment presents for pharma companies. However, the pharma sector is proving resilient, and we are projecting 4.4% global growth for the year ahead. Yet it remains that the current economic picture is inverting some baseline assumptions from previous quarterly forecasts and altering which markets we expect the key growth levers to derive from. Download our latest executive summary for a snapshot view of what our clients use to formulate winning strategies.
by GlobalData
Enter your details here to receive your free Report.

Topline results from NORSE 3 demonstrated bevacizumab-vikg had a similar safety profile to Roche’s Avastin (bevacizumab), as found in the 2011 CATT study. NORSE 3 reported no serious adverse events (SAEs) associated with the treatment. While 20 out of 197 patients suffered an AE in the study eye, these were associated with administration rather than treatment, according to a 31 March company media release. The safety outcomes were the frequency and incidence of AEs and changes in safety parameters, said Outlook.

The anti-VEGF recombinant monoclonal antibody (mAb) previously had an LoA of 37% for DME and 11% for BRVO. Based on GlobalData’s analysis using a combination of machine learning and a proprietary algorithm, the LoA for DME has risen to 44%, while bevacizumab-vikg’s chances in BVRO have increased to 21%. Anti-VEGFs work by targeting the VEGF protein that promotes abnormal blood vessel growth.

On 31 March, this news service reported that Outlook’s registrational Phase III NORSE 2 trial of bevacizumab-vikg in wet-AMD would reach superiority over its comparator, Roche’s Lucentis (ranibizumab), and likely get approval. However, a poor trial design that underdosed the control arm would limit physicians’ confidence and in turn uptake.

Sean Rai-Roche is a Healthcare Reporter for Clinical Trials Arena parent company GlobalData’s investigative journalism team. A version of this article originally appeared on the Insights module of GlobalData’s Pharmaceutical Intelligence Center. To access more articles like this, visit GlobalData.

 

Related Companies

Free Report
img

What is the Global Healthcare and Pharma Market Q2 Outlook?

Given the background of high inflation, re-emerging supply chain issues, and the widespread macro-economic implications of the Ukraine conflict, the global pharmaceutical industry is facing an entirely new set of challenges following the turbulence of the COVID-19 pandemic. GlobalData’s World Markets Healthcare (WMH) service has released its latest Q2 forecast. This report incorporates the latest thinking on the opportunities and risks this new environment presents for pharma companies. However, the pharma sector is proving resilient, and we are projecting 4.4% global growth for the year ahead. Yet it remains that the current economic picture is inverting some baseline assumptions from previous quarterly forecasts and altering which markets we expect the key growth levers to derive from. Download our latest executive summary for a snapshot view of what our clients use to formulate winning strategies.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena